Upstaza, another AAV2-based therapy, was approved by the European Medicines Agency for severe aromatic L-amino acid decarboxylase (AADC) deficiency following intraparenchymal injection. The gene discussed is DDC; the disease is aromatic L-amino acid decarboxylase deficiency.